Acetyl tetrapeptide-5
is used in cosmetic eye formulations to decrease puffiness, eye bags, and dark circles by reducing edema and protecting proteins such as SOD from glycation
Alanine
Ala / A · hydrophobic residue · neutral charge
AOD-9604
is studied as an anti-obesity peptide that can reduce weight gain and increase fat oxidation in obese animal models with generally neutral effects on IGF-1 and glucose metabolism in early human trials
Arginine
Arg / R · basic residue · positive charge
Argireline
is a topical cosmetic peptide reported to decrease dynamic wrinkles by partially mimicking the mechanism of botulinum toxin in a non-invasive manner
Asparagine
Asn / N · polar residue · neutral charge
Aspartic acid
Asp / D · acidic residue · negative charge
BPC-157
is investigated for accelerating healing of gastrointestinal mucosa, tendons, ligaments, bone, and nervous tissue in preclinical models, with anti-inflammatory and pro-angiogenic effects
Comparison
While Liraglutide is approved for type 2 diabetes and weight management, improving glycemic control and inducing weight loss through GLP-1–mediated insulinotropic, glucagonostatic, and appetite-suppressing actions6880, Snap-8 is a cosmetic peptide studied for reducing wrinkle depth by inhibiting synaptic vesicle fusion and subsequent muscle contraction in facial expression muscles5060.
While Liraglutide works as a human GLP-1 analog with a single amino-acid substitution (Lys34→Arg) and a C16 palmitoyl fatty acid attached to Lys26 via a glutamate linker, producing a long-acting GLP-1 receptor agonist6880, Snap-8 is acetyl octapeptide-3 (Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2), an extended analog of Argireline derived from the N-terminal region of SNAP-25 that competes with native SNAP-25 for binding to syntaxin-1, forming a non-functional SNARE complex and reducing neurotransmitter release5060.
Liraglutide
GCG
Snap-8
Not assigned in the current dataset.
Liraglutide and Snap-8 are noticeably different, with limited direct overlap in their usual biological context. Their typical research and application settings separate fairly clearly: Liraglutide is more often discussed in the realm of Metabolic and endocrine, whereas Snap-8 is more often associated with the realm of Dermatology and aesthetics. They also influence different molecular systems, with Liraglutide tracking more closely to GLP-1 receptor while Snap-8 centers more on SNARE complex. Liraglutide has a more synthetic analog origin, while Snap-8 is closer to synthetic design background and their development context also differs, with Liraglutide approved while Snap-8 is cosmetic grade. Liraglutide takes the form of a peptide conjugate, whereas Snap-8 is closer to a linear peptide, Liraglutide carries palmitoylation features, while Snap-8 instead reflects acetylation changes; while their sequence patterns also diverge, with Liraglutide showing alpha-helical domain features and Snap-8 showing protein-mimetic sequence features.